Due to their thermosensitivity, most vaccines must be kept refrigerated from production to use. To successfully carry out global immunization programs, ensuring the stability of vaccines is crucial. In this context, two important issues are critical, namely: (i) predicting vaccine stability and (ii) preventing product damage due to excessive temperature excursions outside of the recommended storage conditions (cold chain break). We applied a combination of advanced kinetics and statistical analyses on vaccine forced degradation data to accurately describe the loss of antigenicity for a multivalent freeze-dried inactivated virus vaccine containing three variants. The screening of large amounts of kinetic models combined with a statistical model selection approach resulted in the identification of two-step kinetic models. Predictions based on kinetic analysis and experimental stability data were in agreement, with approximately five percentage points difference from real values for longterm stability storage conditions, after excursions of temperature and during experimental shipments of freezedried products. Results showed that modeling a few months of forced degradation can be used to predict various time and temperature profiles endured by vaccines, i.e. long-term stability, short time excursions outside the labeled storage conditions or shipments at ambient temperature, with high accuracy. Pharmaceutical applications of the presented kinetics-based approach are discussed.
Introduction
The thermal sensitivity of formulated biologics, including vaccines, is a critical factor impacting product quality and potency, hence influencing their worldwide distribution [1, 2] . The thermal stability of vaccines is of concern to the vaccine industry, health authorities, government institutions, and philanthropic organizations attempting to increase the distribution of vaccines to people living in countries with poor infrastructure, unreliable transportation and substandard storage facilities for the preservation of vaccines requiring refrigeration [3] .
World Health Organization (WHO) sets guidelines for the stability evaluation of vaccines [4] and recommends conducting regular and accelerated stability studies. These guidelines aim to provide a framework for shelf life and storage conditions, monitor vaccine stability in the post licensure period and support manufacturing changes by demonstrating consistency of vaccine batches. Such guidelines can be used for the selection of optimal stabilizing conditions, shelf life estimation, temperature excursion modeling, and investigation of changes to manufacturing process that may potentially alter vaccine stability [5] . Many different stability indicating assays can be used, including viral titer, immunochemical assays, liquid chromatography and gel electrophoresis [6, 7] . An often used parameter is shelf life, this refers to the time period during which a drug product remains capable of acceptable performance. Several shelf life estimation methods exist, those described in International Conference on Harmonisation (ICH) guidelines [8] are generally based on linear or nonlinear regression and statistical modeling through poolability tests. Focusing on the fact that an agreement does not currently exist, an investigation of current statistical methods for estimating shelf life, based on stability data, was conducted by a Product Quality Research Institute (PQRI) working group [9] . Additionally, to improve ICH procedure, the application of quantile regression or mixed model tolerance interval methods and batch effects, was proposed [10, 11] .
Kinetics is typically used to estimate vaccine degradation rates through accelerated stability programs which expose products to temperatures greater than those recommended for vaccine storage (typically 5°C, 25°C, 37°C). During kinetic analysis of the data, very often the simplified kinetics models, such as zero-or first order mechanisms, are considered. Such models fail to correctly describe the complicated course of decomposition of biological materials, which frequently show complex and multi-step degradation behavior [12] [13] [14] [15] . The rate constant derived from simplified models are often of little value during kinetic workflow; for example the determination of the kinetic values of pre-exponential factor and activation energy from the Arrhenius plot [7, 16] . Superior kinetic description of the experimental decomposition data of biologicals [17, 18] was obtained with kinetic parameters derived from two-step models, these better mimic the complicated decomposition of the investigated samples. Also of great use is the Šesták-Berggren approach [19] , being a phenomenological kinetic model which allows kinetic analysis, even of complex reactions [14, 20] .
In this report, we applied a general procedure combining advanced kinetic and statistical analyses of vaccine forced degradation data to identify kinetic models which best describe loss of antigenicity for three variants of inactivated viruses in freeze-dried form. Kinetic analysis was applied to predict the long-term vaccine degradation of the freeze-dried products, either under isothermal or specific temperature excursions. Additionally, the antigenicity recoveries predicted by kinetic models were compared with the experimental data of tested samples. Pharmaceutical applications of the presented kinetics-based approach are discussed.
Material and methods

Materials
A multivalent freeze-dried inactivated vaccine by Sanofi Pasteur was used for this study; it is composed of three different viral variants referred as A, B, C. To allow the detection of the antigenicity recovery losses during temperature excursions outside of the refrigerated storage condition (cold chain break), a thermosensitive formulated product was selected. Final bulk products were prepared using an appropriate stabilizer containing a mixture of excipients (amino acids, sugar, surfactant and chelator) in a HEPES buffer to maintain pH at 7. All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). 0.5 mL of final bulk products were dispensed in 3 mL type I glass vials partially stoppered with septum closure and subsequently freeze-dried, then fully stoppered and crimped with aluminum cap. Dried products were investigated with low residual moisture content (0.7%) measured by coulometric titration (Karl Fisher).
Antigenicity was tested by enzyme-linked immunosorbent assay (ELISA) at different time intervals.
Stability monitoring and antigen content by ELISA
Product stability was studied by storing freeze-dried formulations at 5°C, 25°C, 37°C and 45°C into temperature-controlled incubators for up to 6 months. This forced degradation plan was carefully designed to obtain experimental datasets able to be fitted by the software, with a minimum of 20 data points in total obtained at three or more storage temperatures, with significant degree of reaction reached for the more drastic condition. Hence, time intervals for the forced degradation plan were chosen, as follows: 0, 30, 90 and 180 days at 5°C; 7, 14, 30, 60, 90 and 180 days at 25°C; 1, 3, 7, 14, 30, 60 and 180 days at 37°C, and 1, 3, 7, 14, 30 and 90 days at 45°C.
During studies of the influence of temperature excursions, the two following temperature programs were applied to freeze-dried products before analysis by ELISA: (i) 1 month at 5°C, followed by 9 months at 25°C and then returned to 5°C for 2 months; (ii) 1 month at 5°C, followed by 6 months at 37°C and then returned to 5°C for 4.5 months. To evaluate the impact of experimental shipments under uncontrolled cold chain conditions, product samples kept for 534 days (∼1.5 year) at 5°C were shipped from Lyon (France) to Toronto (Canada) at ambient temperature. Another set of samples was also sent from Lyon (France) to Barcelona (Spain). Real temperature profiles were recorded with temperature monitoring devices (TempTale®4 USB Monitors, Sensitech Inc., Beverly, USA) placed into the box containing the vaccines. The temperature profiles recorded continuously during shipment were used for predictions. All samples came back to France and were kept at 5°C before ELISA analyses.
The antigen titer of vaccine samples was determined by a variantspecific sandwich ELISA. Freeze-dried products were stored at 5°C before analysis and reconstituted extemporaneously prior to testing. Three vials were analyzed for each kinetic time point and a mean of these independent dosage values was displayed. Results are systematically expressed as a percentage of the mean value at T = 0 and referred to as antigen recovery. To estimate prediction accuracy, percentage point was used as the arithmetic difference between antigenicity recoveries, experimentally determined and predicted.
Advanced kinetic analyses
A general stability modeling procedure using AKTS-Thermokinetics software [21] (version 4.1, AKTS AG, Advanced Kinetics and Technology Solutions, Siders, Switzerland) was already described in detail [20] and applied to predict stability for various products constituting vaccines [14] . Briefly, according to a least-squares regression analysis, the software uses 'one-step' and 'two-step' kinetic models based on the truncated Šesták-Berggren equation ('two-step' in Eq. (1) to determine the function(s) which best fits the experimental data. Hence, reaction rate was described as follows [20] :
With α: the reaction progress, A: pre-exponential factor, E: activation energy, n: reaction order, m: a parameter introduced to take into account the possible autocatalytic behavior of reaction (1) and (2), for the first and second step, respectively. During evaluation one, two or more reaction stages may be considered, depending on the complexity of the reaction. For a two-step reaction, consecutive and competitive type models were screened. Competitive two-step models use one more adjustable parameter than consecutive two-step model, with the contribution of the reaction rate of the first and second stage to the overall reaction rate. The quality of regression fit is quantified according to RSS (Residual Sum of Squares) value. The combination of different kinetic models best describing the reaction course is identified with software according to the higher Akaikie Information Criteria and Baysian Information Criteria weighted scores, referred to as wAIC and wBIC, respectively. In kinetic analysis, when applying the different models describing the reaction course, an important issue is to find the best method for their discrimination [22] . The criteria for comparing models applied in this study were based on the information theory introduced by Akaike [23] and its Bayesian counterpart [24, 25] . Both these criteria indicate not only which model is more likely to better fit the analyzed data, but also allow quantification of likelihood. An example of criteria application, using limited experimental points for the prediction of thermal stability of biological materials, is described in detail elsewhere [20] . Finally, by using the selected model, the software was employed to run bootstrap analysis (resampled 1000 times with replacement) and determine the confidence intervals (CI), in the form of the upper and lower 95 percentiles (predictive band at 95%), which were evaluated for each of the fitted parameters [20] . After determination of the best kinetic models the software was able to simulate the reaction progress during arbitrarily chosen aging time and under any temperature profiles. We have used this approach to continuously predict degradation progresses of variants when vaccines were kept under isothermal conditions (long-term stability), during temperature excursions and during exposures under real atmospheric temperature profiles (e.g. shipments at ambient temperature).
Results
Thermal degradation of virus-based vaccine described by two-step kinetic models
Lots of models, starting from the simplest ones (zero and first-order) and ending with more complex were screened to fit the six months experimental data. The kinetic parameters (A, E, n, m) were systematically adjusted during the fitting procedure, comprising 'one-step' or 'two-step' kinetic models. The software compared and ranked the models from the worst to the best, for each variant. One-step models such as zero-and first-order kinetics did not correctly fit experimental data, especially at temperatures higher than 5°C for variant A and C ( Fig. 1, left) . Better fits were obtained by using two-step models for all variants ( Fig. 1, right) . Based on ranking statistical scores wAIC and wBIC, competitive two-step model containing six adjustable kinetic parameters were selected, since they provided the best quality of fit (low RSS value) and best wAIC and wBIC scores. It was confirmed for all three serotypes, with wAIC and wBIC scores at least equal to 15% (Tables S1-S3) , in contrast to the other scores, close to zero, obtained with one-step and consecutive two-step models (Tables S1-S3 ). Firstly, this means that the adjustable kinetic parameters used with one-step models were not enough to fit datasets, and secondly, that competitive models were preferred to consecutive models for two-step type kinetics. Consequently, the most appropriate kinetic models for variants A, B, and C were competitive two-step models, mathematically described as follows:
Variant A: 
Variant B: 
Variant C: 
where for example, in Eq. (2), the values 0.409 and 0.591 represent the contribution of the reaction rates of the first and second stages of the overall reaction rate, . All three variants were described with competitive two-step models containing fixed order, from n = 1 to n = 4 (Eqs. (2)- (4)). Based on experimental data generated for up to 6 months, the respective models were used for the simulation of stability for 3 years at 5°C, 25°C, 37°C and 45°C (Fig. 2, left) . For the three variants, loss of antigenicity exhibited first a rapid initial decay followed by a gradual decrease (Fig. 2, left) . The initial loss of antigenicity occurred with a magnitude depending on incubation temperatures and variants. At 5°C, the first step of the degradation process reached an antigenicity recovery of around 85%, 90% and 72% after approximately 1 year, 0.5 year and 1.5 years for variants A, B and C, respectively (Fig. 2, left) . Then, the second step of the degradation process was predicted to be more gradual and slowly reached an antigenicity recovery around 80%, 88% and 67% for variants A, B and C, respectively after 3 years at 5°C (Fig. 2, left) . This two-step degradation behavior looked more pronounced with higher storage temperatures and depending on variants.
As an example, 50% of antigenicity recovery was predicted to be reached after 2 years at 25°C for variant A, 1.5 years for variant C and for variant B 3 years and beyond (data not shown), making this obviously the more thermostable variant (Fig. 2, left) . Incubation at high temperatures (37°C, 45°C) rapidly induced loss of antigenicity of several tens of percents (Fig. 2, left) . This phenomenon was especially pronounced for variant C, obviously the more thermosensitive variant.
Focusing on 5°C, the experimental data generated for 6 months are inside the predictive band determined by bootstrap analysis (CI 95% - Fig. 2, right) . The same was observed for 2.5 months data originating from another batch (Fig. 2, right, open triangles) . Similarly, further experimental data (obtained later) not included in kinetic modeling, collected after 1.8 years at 5°C for all variants and after 2.8 years for variant A, were mostly contained within the predictive bands (Fig. 2,  right) . Only one of the three data points was outside the predictive band for variant B. Quantitatively, predictions were performed for each variant based on their respective two-step models (Eqs. (2)- (4)), assuming an aging of 1.8 years at 5°C. Antigenicity recoveries, which were predicted at 82%, 89% and 68% for variants A, B and C, respectively, were later confirmed by real stability data, with approximately five percentage points difference from experimental values ( Table 1) .
3.2.
Vaccine stability predicted during excursions of temperature 3.2.1. Confronting vaccine stability predictions with real data obtained after experimental temperature excursions for months at 25°C and 37°C
Based on kinetic modeling performed with 6 months forced degradation data, selected 'two-step' models (Eqs. (2)-(4)) were applied to temperature excursion to determine if antigenicity of variants could be adequately predicted. Since the recommended vaccine storage condition is 5°C ± 3°C, excursions to higher temperatures (9 months at 25°C and 6 months at 37°C) were applied to assess the degree of degradation obtained at other arbitrarily selected storage conditions and verify the simulated predictions. Antigenicity changes under these temperature excursions were simulated on the basis of the selected model. Gradual decreases were predicted for all variants during exposure at elevated temperatures, except for variant B at 25°C (Fig. 3) .
In that particular case, no significant loss of antigenicity was predicted when compared to sample kept at 5°C (Fig. 3, left, middle) , indicating a lower thermal sensitivity for variant B, compared to variants A and C. In the same condition, at 25°C, antigenicity evolution were predicted in two stages for variant A and C, with a rapid initial decrease followed by a more gradual loss of antigenicity (Fig. 3, left, top and bottom) . It should be noted that variant C exhibited a faster initial degradation profile when exposed at elevated temperature (Fig. 3, bottom) , indicating a particular thermosensitivity for this variant. Finally, exposure at 37°C induced pronounced loss of antigenicity for all variants, with two-step profiles (Fig. 3, right) . Quantitatively, antigenicity recoveries were predicted at 72%, 86% and 58% for variants A, B and C, respectively when vaccine was exposed for 9 months at 25°C ( Table 2) . Those predictions were later confirmed experimentally, with less than five percentage points difference from experimental values ( Table 2 ). In addition, predictions based on two-step kinetic models indicated that exposure of vaccine for 6 months at 37°C induced a loss of antigenicity recoveries up to 44%, 60% and 24% for variants A, B and C, respectively. Experimental data obtained by ELISA were included in the predictive band (CI 95%), confirming agreement between antigenicity recovery predictions and experimental data with not more than five percentage points difference (Table 2 ).
Confronting vaccine stability predictions with real data obtained after shipment of products at ambient temperatures
Recorded oscillations around ambient temperature indicated minimum/maximum temperatures at 21°C/27°C during shipment to Toronto and at 4°C/48°C during shipment to Barcelona (Fig. 4) . Gradual decreases of antigenicity for all the three variants were predicted by the software (Eqs. (2)- (4)) depending on the recorded temperature profiles (i.e. for shipment in Barcelona - Fig. 4 ). Predictions identified variant B as the most stable and variant C as the least stable. Quantitatively, antigenicity recoveries after the Lyon -Barcelona round trip were predicted at 81%, 88% and 66% for variants A, B and C, respectively (Table 3) . Those predictions were later confirmed experimentally, with approximate five percentage points difference from experimental values (Table 3) . Interestingly, similar antigenicity recoveries were obtained after the return flight between Lyon and Toronto (82%, 89% and 67% for variants A, B and C, respectively - Table 3) .
To assess the impact of maintaining freeze-dried products at ambient temperature for an extended period of time, we designed a case study using simulations of storage at ambient temperature in Kenya (Mombassa) and Argentina (Buenos Aires). The software mimicked the real atmospheric temperature profiles in both locations, with oscillations between 23°C and 32°C for Mombassa, and between 4°C and 30°C for Buenos Aires (Fig. S1 ). The impact of such storage outside the standard refrigerated conditions on vaccine antigenicity was predicted for 2 years for variant A, B and C as a rapid initial loss of antigenicity, followed by a gradual decrease (Fig. S1 ). The first degradation step predicted a loss of antigenicity of variant A to approximately 79% and 72% in Buenos Aires and Mombassa, respectively (Fig. S1) , and a gradual decrease to approximately 72% and 64% after 2 years, in Buenos Aires and Mombassa, respectively (Fig. S1 ). For comparison, antigenicity recovery of variant A kept under refrigerated conditions (2-8°C) for 2 years was predicted at 82%. For variant B, the first predicted degradation step amounted to approximately 90% in both countries, followed by a gradual decrease to approximately 87% and 79% after 2 years in Buenos Aires and Mombassa, respectively (Fig. S1) . Finally, the predictions for variant C indicated a loss of antigenicity up to approximately 65% in both countries for the first rapid step, and to approximately 60% and 40% after 2 years in Buenos Aires and Mombassa, respectively (Fig. S1 ).
Discussion
In this study, an experimental vaccine used as complex biomaterial 
Table 1
Comparison of antigenicity predicted by kinetic models (one-step and two-step) with experimental data (average of three independent ELISA results ± standard deviation) for vaccine containing variants A, B and C kept under refrigerated conditions (2-8°C). Differences between prediction and experimental antigenicity recovery are displayed (percentage point).
Time under refrigerated conditions Antigenicity recovery (%) and containing three variants (variant A, B and C) was thermally stressed in a forced degradation program comprising of four incubation temperatures ranging between 5°C and 45°C. Vaccine antigenicity was periodically evaluated by ELISA up to 6 months for each variant. No or partial fit of experimental data was shown when zero-and first-order kinetics were applied, leading to long-term antigenicity predictions overestimated by up to 25%. Software such as ASAPprime® [26, 27] and ScienTek® [28] are not able to correctly describe the course of the complex degradations of viruses studied here. AKTS-Thermokinetics software [21] however, applies simultaneous combination of two-step 
Table 2
Comparison of antigenicity predicted by two-step models with experimental data (average of three independent ELISA results ± standard deviation) for vaccine containing variants A, B and C, subjected to customized temperature excursions at 25°C and 37°C. Differences between prediction and experimental antigenicity recovery are displayed (percentage point).
Shipments and storage conditions Antigenicity recovery (%) Two-step model
Variant Experimental data ± SD (%) Prediction (%) Percentage point (%) 1 month in a cold chamber (2-8°C), followed by 9 months in an incubator set at 25°C, then returned to the cold chamber for 2 months 
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models enabling the consideration of an unlimited amount of kinetic models, for the best description of the reaction course. When complex degradation progresses were observed experimentally, it was demonstrated that the application of wAIC and wBIC scores allowed determination of whether one or two-steps model was more likely to be correct [20] . These criteria take into account not only the quality of fit, such as the sum of residual squares (RSS), but also the number of experimental points available and model parameters used. Additionally, they determine which model is more likely to be correct, and quantify how much more likely. Hence, possible errors of over-fitting were avoided, and it was statistically confirmed that the two-step models better describe the loss of antigenicity of variants A, B and C. Thus, exhibiting highest statistical scores (wAIC and wBIC), competitive two-step models were selected for each variant (see Eqs. (2)- (4) and Tables S1-S3) , describing a rapid initial loss of antigenicity followed by a gradual decrease. Two-phase degradation profiles have already been described during accelerated stability studies of several viruses (measles vaccine [29] , attenuated RBOK vaccine [30] , canine distemper vaccine [31] , ALVAC poxvirus [14] , and a freeze-dried live, attenuated virus vaccine [15] ). For these enveloped viruses, from different viral families, two steps in the degradation process is also described (initial rapid drop followed by a long gradual decrease phase), regardless of the readout used (infectious tiers, antigenic titers etc.) [15, 29, 32] . One hypothesis put forward in such forced virus degradation studies is that this biphasic behavior entails the presence of at least two components with different inactivation kinetics which are affected by the thermal treatment [29, 32] (e.g. epitope unfolding, capsid integrity loss, major virus conformational reorganization, key protein functionality loss or any adaptive viral strategy). It is important to mention that many chemical degradations and physical transitions occur during virus thermal degradation. The selection of two-step reactions model is purely based on the statistical analysis and goodness of fit with two major pathways of phenomenological kinetic model of the reaction rate, which are most likely built up from the sum of multiple reactions. At that point, it is necessary to clearly underline that this result does not have a real mechanistic basis, but it rather only depicts a phenomenological mathematical model applied for fitting the reaction course. Kinetic models mathematically described in Eqs. (2)- (4) for variant A, B and C respectively, showed a higher contribution of the second step (gradual decrease of antigenicity) as compared to the first step (rapid loss of antigenicity). This is particularly marked for variant B, indicating that stability is mainly governed by the second step with a contribution of 88.5%, as compared with the first step at 11.5% (Eq. (3) . This very slow rate of antigenicity decrease predicted by the kinetic model was found to be in agreement with real stability data presented in this study (Figs. 2 and 3, Tables 1 and 2) . Variant B was shown to be the most thermostable vaccine variant.
Conversely, results obtained demonstrated that kinetic models describing degradation changes of variants A, B and C are able to accurately predict vaccine stability under any kind of storage conditions, with just a few percentage points difference from experimental values (Tables 1-3) . First of all, long-term stability at usual recommended storage temperature for freeze-dried product (5°C ± 3°C) was predicted with success for all variants, with less than 6% as differences between predicted and experimental values ( Table 1 ). The use of the Monte Carlo method, such as bootstrap analysis, provides accurate predictions. It was already shown that the bootstrap CI gives a tight and realistic estimate of the true CI [33] . One of the main interests of bootstrap CI determination is that this approach takes into account the scattering of experimental data without imposing a Gaussian distribution around predicted values, and that it does not need to know the standard deviation of the analytical technique used. For the prediction of degradation processes, the lower 95 percentile (predictive band at 95%), obtained with bootstrap analysis, can advantageously be used to determine product shelf life, i.e. time to reach the lowest acceptable specification value. This approach could improve applicable standards used to determine shelf life, such as compliance with the acceptance criterion as the time associated with the last measurement within the specification [4] .
Our results confirm that the impact of experimental shipments with rupture in the cold chain and short time excursions above 40°C can be predicted with high accuracy. During shipments to Lyon-Barcelona and Lyon-Toronto, predictions in term of antigenicity losses were confirmed by experimental ELISA data, with no more than 6% expressed as differences between predicted and experimental values (Table 3) . Interestingly, even if temperature excursions endured by freeze-dried products during our experimental shipments were different, including different gaps between the minimum and the maximum exposure temperatures, similar predictions were obtained regarding the level of Table 3 Comparison of antigenicity predicted by two-step models with experimental data (average of 3 independent ELISA results ± standard deviation) for vaccine containing variants A, B and C, subject to experimental shipments performed at ambient temperature. Differences between prediction and experimental antigenicity recovery are displayed (percentage point).
Storage conditions
Antigenicity recovery (%) degradation of variants. This observation could be explained by the fact that shipments were performed after 1.5 years of storage at 5°C. Indeed, after this period of time, the initial rapid loss of antigenicity was passed and samples were in the second step of the degradation process, engaging thermo-resistant behavior with a gradual decrease of antigenicity. As shipments were executed during the stable phase, it could be assumed that variants were less impacted by temperature oscillation profiles, which could explain why antigenicity losses were similar despite such different shipment conditions (by car to Barcelona and by plane to Toronto). In addition, the simulation indicated that these shipments, performed at ambient temperature, did not dramatically impact antigenicity level when compared to shipments performed under controlled refrigerated conditions at 5°C. Thus, predicted antigenicity values only differed by 2.5% between experimental shipments Lyon-Barcelona performed under controlled cold chain versus ambient temperature. This result illustrated how kinetic-based modeling could help to recommend storage conditions for vaccine shipments and to evaluate the quality of vaccine under any temperature exposure. Kinetic-based modeling approach presented in this work can advantageously be used to evaluate impact of storage temperature on vaccine quality. It was illustrated by simulating antigenicity losses for variant A, B and C during 2 years under different storage conditions (i.e. ambient temperature in Mombassa, in Buenos Aires and under refrigerated conditions). Depending on variants, antigenicity losses reached from 10% to 60% for a vaccine kept at ambient temperature, whereas for vaccines kept in refrigerated conditions the losses were limited to approximately 10% to 30%. One can take advantage of such long-term predictions to justify, document and recommend the storage temperature of products. Improvements in knowledge of vaccine stability behavior, and their thermosensitivity level could certainly have economic impacts and financial gain.
It was stated that the inherent temperature sensitivity of vaccines is particularly significant for live virus-based vaccines that require careful control of the storage cold chain [34] . As the cold chain in the last mile is particularly demanding, a controlled temperature chain (CTC) label [35] was recently implemented to ensure that vaccines can withstand a temperature excursion up to 40°C for up to four days. The kinetic-based approach described here could easily, and advantageously, be used to predict degradation profiles of vaccines during storage at 40°C for four days. In addition, kinetic modeling is able to predict the impact of any kind of temperature excursions, independent of their complexity provided that temperature was accurately recorded and used for prediction. Hence, new ways of supply chain management could emerge. The accurate prediction of changes in vaccine properties during shipment would require appropriate controlled temperature monitoring which, in turn, allows the use of real temperature profiles in the kinetic analysis. Hence, electronic time-temperature devices would be able to inform, in real time, the level of vaccine degradation provided that specific and convenient kinetic models such as the ones described in this study could be integrated into compact and connected devices, suggesting real-time tracking of temperature excursions could be achieved. This could be of major interest, knowing that maintaining the cold chain for storing and transporting vaccines is often difficult for health workers in poor countries, especially in remote areas. The WHO has stated that as many as 25% of all vaccine products reach their destination in a degraded state [3] and it was demonstrated that major providers expose vaccine products to inappropriate temperatures [36] . Considering that the cold chain, from production to use of vaccines, amounts to about 80% of the total cost of vaccination programs [37] , supply chain product management integrating kinetic modeling could significantly reduce financial losses due to cold chain breaks.
Finally, the experimental and thermosensitive virus-based vaccine used for this study, can be considered as one of the most complex biomaterials with multi-step degradation processes. Therefore, it is rational to assume that stability behavior of other biologicals (e.g. peptides, viral vectors, monoclonal antibodies, antibody-drug conjugates) and adjuvants (e.g. emulsions, immunomodulators) could also be successfully predicted. Such forecasts may significantly support the formulation, process development and help in optimization of supply chain procedures.
Conclusion
A kinetic-based modeling approach was studied to evaluate inactivated virus-based vaccine stability, estimate impact of temperature excursions outside recommended storage conditions and predict the long-term stability of a vaccine containing three variants (variant A, B and C), formulated as a freeze-dried product. Based on two-step kinetic models, losses of virus antigenicity were accurately predicted for freezedried product in isothermal long-term storage conditions, as well as in real temperature profiles (i.e. temperature excursions during shipments, maintaining vaccine products at ambient temperature in different climatic zones). Based on experimental data collected during several months, these results uncover the potential of a kinetic-based modeling approach to (i) predict shelf life of vaccines, (ii) recommend appropriate storage conditions, and (iii) evaluate the impact of temperature excursions (cold chain breaks), with an error amounting to approximately five percentage points. From these results, it seems reasonable to assume that development of recommendations, based on advanced kinetics and stability modeling approaches can be a very useful tool. It can also support the conclusions gained from procedures described in international guidelines [8, 38, 39] . The application of advanced kinetic software may have a significant impact on shortening time-consuming shelf life determinations, evaluating impact of temperature excursions on vaccine efficacy, and evaluating the pharmaceutical product stability of vaccines, monoclonal antibodies, antibodydrug conjugates, peptides and viral vectors.
